Soleno Therapeutics Inc header image

Soleno Therapeutics Inc

SLNO

Equity

ISIN null / Valor 121339545

NASDAQ (2026-04-02)

USD 39.49+6.76%

Soleno Therapeutics Inc
UMushroom community rating:

4.13 8 votes No rating yet

NegativeNeutralPositive

About company

Soleno Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for rare diseases. The company's primary focus is on its lead candidate, DCCR (Diazoxide Choline) Extended-Release tablets, which are designed as a once-daily oral treatment for Prader-Willi syndrome (PWS), a complex genetic disorder. Currently, DCCR is undergoing evaluation in a Phase 3 clinical development program. Soleno aims to address unmet medical needs by providing safe and effective therapeutic solutions that enhance the quality of life for patients with life-threatening rare conditions.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-46.4%1Y

1,745%3Y

101%5Y

Performance

73.0%1Y

127%3Y

119%5Y

Volatility

2039 M

Market cap (USD)

3,575,161

Daily traded volume (Shares)

45.46 / 43.99

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.13

8 votes

Performance:

4.00

Innovation:

4.13

Society:

3.86

Nature:

3.88

Yiling Guo

United Kingdom, 09 Nov 2025

Good financial performance and under valued

Aditya Jain

United Kingdom, 09 Nov 2025

Good

Meruert Daniyarkyzy

United Kingdom, 09 Nov 2025

Volatile and high risk, but offers notable upside potential if its lead treatment succeeds.

EQUITIES OF THE SAME SECTOR

UCB SA

UCB SA Valor: 986410

Annual Return

-50%0%+50%

Risk level

110

-1.23%EUR 264.50

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc Valor: 33395434

Annual Return

-50%0%+50%

Risk level

110

3.22%USD 546.89

Demant A/S

Demant A/S Valor: 32651962

Annual Return

-50%0%+50%

Risk level

110

0.88%DKK 195.60

Ambu A/S

Ambu A/S Valor: 39639588

Annual Return

-50%0%+50%

Risk level

110

0.95%DKK 69.05

H. Lundbeck A/S

H. Lundbeck A/S Valor: 119252587

Annual Return

-50%0%+50%

Risk level

110

2.21%DKK 40.78

Embla Medical hf

Embla Medical hf Valor: 1060135

Annual Return

-50%0%+50%

Risk level

110

1.89%DKK 27.00

Lineage Inc

Lineage Inc Valor: 136372357

Annual Return

-50%0%+50%

Risk level

110

0.46%USD 32.93

Bausch Health Companies Inc

Bausch Health Companies Inc Valor: 42260834

Annual Return

-50%0%+50%

Risk level

110

-3.86%USD 5.37

Dyne Therapeutics Inc

Dyne Therapeutics Inc Valor: 56806425

Annual Return

-50%0%+50%

Risk level

110

4.09%USD 18.84

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc Valor: 22860122

Annual Return

-50%0%+50%

Risk level

110

4.81%USD 22.45

SIX

FactSet

Clearbit

Logos provided by Clearbit